A Case of Advanced Thymic Carcinoma in Which Carboplatin and Nab-paclitaxel Were Significantly Effective After Progression on Lenvatinib

DOI Web Site 11 References
  • Mizuta Remi
    Department of Respiratory Medicine, Nagasaki University Hospital
  • Fukuda Minoru
    Department of Respiratory Medicine, Nagasaki University Hospital Clinical Oncology Center, Nagasaki University Hospital
  • Suyama Takayuki
    Department of Respiratory Medicine, Nagasaki University Hospital
  • Gyotoku Hiroshi
    Department of Respiratory Medicine, Nagasaki University Hospital
  • Takemoto Shinnosuke
    Department of Respiratory Medicine, Nagasaki University Hospital
  • Yamaguchi Hiroyuki
    Department of Respiratory Medicine, Nagasaki University Hospital
  • Sawai Toyomitsu
    Department of Respiratory Medicine, Nagasaki Harbor Medical Center
  • Irie Junji
    Department of Pathology, Nagasaki Harbor Medical Center
  • Ashizawa Kazuto
    Clinical Oncology Center, Nagasaki University Hospital Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences Clinical Genomics Center, Nagasaki University Hospital
  • Mukae Hiroshi
    Department of Respiratory Medicine, Nagasaki University Hospital

Bibliographic Information

Other Title
  • レンバチニブ増悪後にカルボプラチンとnab-パクリタキセルが著効した進行胸腺癌の1例

Search this article

Abstract

<p>Background. Since there is no insurance-approved drug for thymic carcinoma in Japan, drugs for other cancers are being used provisionally. In 2021, lenvatinib was approved for unresectable thymic carcinoma. Case. A 54-year-old woman visited a nearby doctor with a complaint of left chest pain. Chest CT showed an anterior mediastinal tumor, multiple masses of the left pleura, and left pleural effusion. She was diagnosed with thymic carcinoma (pT2N0M1a, stage IVA) by surgical biopsy. Due to the difficulty of hospitalization due to the COVID-19 pandemic and the wish of the patient, lenvatinib was introduced as the first-line treatment in an outpatient setting. However, her condition worsened and her chest pain increased. When carboplatin and nab-paclitaxel were given as second-line treatment, the tumor in the anterior mediastinum, multiple pleural tumors, and mediastinal lymph nodes were remarkably reduced, the left pleural effusion decreased in volume, and the symptoms were alleviated. Conclusion. We experienced a case in which carboplatin and nab-paclitaxel treatment were effective for advanced thymic carcinoma that was resistant to lenvatinib. Although lenvatinib was newly approved, platinum-based chemotherapy is considered an important option in chemotherapy for thymic carcinoma.</p>

Journal

  • Haigan

    Haigan 62 (2), 115-120, 2022-04-20

    The Japan Lung Cancer Society

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top